Fund Iv L.P. Omega Purchases 220,000 Shares of Replimune Group Inc (NASDAQ:REPL) Stock

Share on StockTwits

Replimune Group Inc (NASDAQ:REPL) major shareholder Fund Iv L.P. Omega acquired 220,000 shares of the stock in a transaction dated Monday, November 18th. The shares were acquired at an average cost of $13.61 per share, with a total value of $2,994,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of NASDAQ REPL opened at $13.61 on Friday. The stock has a market cap of $390.50 million, a PE ratio of -10.23 and a beta of 3.30. The company has a quick ratio of 9.85, a current ratio of 9.85 and a debt-to-equity ratio of 0.16. Replimune Group Inc has a 52-week low of $8.88 and a 52-week high of $18.25. The business has a 50-day moving average price of $14.37 and a 200 day moving average price of $13.34.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Monday, November 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Sell-side analysts anticipate that Replimune Group Inc will post -1.4 earnings per share for the current year.

Several research firms have recently issued reports on REPL. Chardan Capital reaffirmed a “buy” rating and set a $28.00 price objective on shares of Replimune Group in a research report on Thursday, October 24th. Roth Capital upped their price objective on Replimune Group from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. ValuEngine raised Replimune Group from a “hold” rating to a “buy” rating in a research report on Tuesday. Zacks Investment Research cut Replimune Group from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $26.00 price objective on shares of Replimune Group in a research report on Monday, September 30th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $23.25.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Morgan Stanley boosted its position in shares of Replimune Group by 793.0% in the 2nd quarter. Morgan Stanley now owns 20,709 shares of the company’s stock valued at $304,000 after purchasing an additional 18,390 shares during the period. Wells Fargo & Company MN boosted its position in shares of Replimune Group by 211.3% in the 2nd quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock valued at $338,000 after purchasing an additional 15,672 shares during the period. Northern Trust Corp boosted its position in shares of Replimune Group by 1.2% in the 2nd quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock valued at $1,817,000 after purchasing an additional 1,437 shares during the period. Citadel Advisors LLC boosted its position in shares of Replimune Group by 5.7% in the 2nd quarter. Citadel Advisors LLC now owns 186,281 shares of the company’s stock valued at $2,731,000 after purchasing an additional 10,009 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Replimune Group by 7.3% in the 2nd quarter. Vanguard Group Inc. now owns 536,564 shares of the company’s stock valued at $7,866,000 after purchasing an additional 36,547 shares during the period. 61.51% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: Diluted Earnings Per Share

Insider Buying and Selling by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Stitch Fix  Given “Buy” Rating at Stifel Nicolaus
Stitch Fix Given “Buy” Rating at Stifel Nicolaus
Uniqure  Earns “Buy” Rating from Mizuho
Uniqure Earns “Buy” Rating from Mizuho
Barclays Reiterates Buy Rating for T-Mobile Us
Barclays Reiterates Buy Rating for T-Mobile Us
Virtus Investment Partners’  Hold Rating Reiterated at Barclays
Virtus Investment Partners’ Hold Rating Reiterated at Barclays
Ionis Pharmaceuticals Inc  Director Sells $63,740.00 in Stock
Ionis Pharmaceuticals Inc Director Sells $63,740.00 in Stock
Rockwell Automation  SVP Ernest Nicolas Sells 121 Shares
Rockwell Automation SVP Ernest Nicolas Sells 121 Shares


© 2006-2019 Ticker Report